Intrawound Administration of Vancomycin in THA

Serum and Wound Vancomycin Levels Following Intrawound Administration in Primary Total Hip Arthroplasty

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT05338008

Enrollment

120

Registered

2022-04-20

Start date

2022-05-01

Completion date

2022-12-31

Last updated

2025-02-04

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hip

Brief summary

The purpose of this study is to determine the intra-articular and serum levels of vancomycin over the first 24 hours postoperatively after intra-articular administration of a standard dose of vancomycin in primary total hip arthroplasty.

Interventions

PROCEDUREIntrawound administration of vancomycin after closure of the arthrotomy

After closure of the arthrotomy, 1 g of vancomycin powder suspended in 30ml of normal saline was injected directly into the joint with an 18-gauge needle.

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

SINGLE (Outcomes Assessor)

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Age over 18; 2. Total hip arthroplasty for advanced hip diseases including femoral neck fracture, developmental dysplasia of hip, and osteonecrosis of the femoral head.

Exclusion criteria

1. Diminished mental capacity 2. Vancomycin allergy 3. Chronic kidney disease stage III and stage IV

Design outcomes

Primary

Measure	Time frame	Description
Intra-articular vancomycin concentration	2 hours, 8 hours and 24 hours postoperatively	—
Serum vancomycin concentration	2 hours, 8 hours and 24 hours postoperatively	—
Renal function	Postoperative Day 1 and Day 3	blood urea nitrogen (BUN), creatinine (Cr), GFR
Blood loss	Postoperative Day 3	—

Countries

China

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026